FDA Approves Altuviiio: Sanofi's Long-Acting Hemophilia A Therapy
Sanofi's Altuviiio has received FDA approval as a long-acting therapy for Hemophilia A, promising to revolutionize treatment for patients with this bleeding disorder.
The FDA approved Altuviiio (efanesoctocog alfa) on February 22, 2023, as a long-acting factor VIII replacement therapy for Hemophilia A. Developed by Sanofi, it enables once-weekly prophylaxis through Fc-VWF-XTEN fusion technology that extends half-life beyond conventional treatments.
Contents9 sections
Key Takeaways
- FDA approval date: February 22, 2023 for adults and children with Hemophilia A
- Clinical evidence: XTEND-1 trial (NCT04161495) showed 77% reduction in annualized bleeding rate versus prior prophylaxis
- Dosing advantage: Once-weekly prophylaxis versus 2-3 times weekly for standard factor VIII therapies
- Mechanism: Fc-VWF-XTEN fusion protein overcomes the von Willebrand factor ceiling limiting conventional therapies
- Indications: Routine prophylaxis, on-demand treatment, and perioperative management
What Is Altuviiio?
Altuviiio (efanesoctocog alfa) is a recombinant factor VIII replacement therapy. The FDA-approved label describes it as an antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein. Sanofi developed it for patients with Hemophilia A, a genetic bleeding disorder caused by factor VIII deficiency.
The therapy combines three molecular components: an Fc domain engaging the neonatal Fc receptor recycling pathway, a von Willebrand factor binding domain for stability, and XTEN polypeptides that increase molecular size. This structure extends factor VIII half-life beyond the VWF ceiling that limits standard therapies.
When Was Altuviiio Approved?
The FDA granted approval on February 22, 2023, following a Biologics License Application submitted by Sanofi. The agency assigned Breakthrough Therapy and Fast Track designations during review, recognizing the unmet need for longer-acting factor VIII products.
The approval covered three indications: routine prophylaxis to prevent bleeding episodes, on-demand treatment for acute bleeding, and perioperative management for surgical procedures. The label specifies use in adults and children with Hemophilia A.
What Did the XTEND-1 Trial Show?
The Phase 3 XTEND-1 trial (NCT04161495) provided primary efficacy data. This open-label study enrolled patients aged 12 years and older with severe Hemophilia A. Participants received once-weekly Altuviiio prophylaxis.
Results showed a mean annualized bleeding rate (ABR) of 0.70 (95% CI: 0.5-1.0) with a median of 0.0. This represented a 77% reduction compared to prior factor VIII prophylaxis. The trial completed enrollment in February 2022.
| Outcome Measure | Result |
|---|---|
| Mean Annualized Bleeding Rate | 0.70 (95% CI: 0.5-1.0) |
| Median Annualized Bleeding Rate | 0.0 |
| Reduction vs Prior Prophylaxis | 77% |
| Trial Status | Completed February 2022 |
How Does Altuviiio Compare to Other Therapies?
Standard recombinant factor VIII therapies require prophylactic dosing 2-3 times per week. Altuviiio's extended half-life enables once-weekly dosing. Sanofi reported this dosing schedule may improve patient adherence and quality of life.
The therapy competes in the extended half-life factor VIII market. Its Fc-VWF-XTEN fusion technology differentiates it from other long-acting products. The Hemophilia A treatment market includes several options, but Altuviiio's weekly dosing interval offers a specific advantage for eligible patients.
What Are the Safety Considerations?
The package insert lists infusion site reactions and headache as common adverse events. Factor VIII inhibitor development remains a concern with any factor VIII replacement therapy. The label includes warnings for hypersensitivity reactions and thromboembolic events.
Post-marketing surveillance continues to monitor long-term safety. The FDA required a Risk Evaluation and Mitigation Strategy focusing on inhibitor development and hypersensitivity reactions.
What Is the Market Impact?
Approximately 20,000 individuals in the United States have Hemophilia A. A subset requires routine prophylaxis. Altuviiio enters a market with existing extended half-life products but offers distinct pharmacokinetic advantages.
Sanofi's pipeline includes Altuviiio as a key growth driver. The company has focused on rare disease and hematology portfolios. This approval strengthens its position in the rare disease treatment sector.
Frequently Asked Questions
What is Altuviiio approved for?
Altuviiio (efanesoctocog alfa) is FDA-approved for routine prophylaxis, on-demand treatment of bleeding episodes, and perioperative management in adults and children with Hemophilia A.
When did the FDA approve Altuviiio?
The FDA approved Altuviiio on February 22, 2023, based on data from the Phase 3 XTEND-1 and XTEND-Kids clinical trials.
How does Altuviiio differ from standard factor VIII therapies?
Altuviiio uses Fc-VWF-XTEN fusion technology to extend factor VIII half-life beyond the von Willebrand factor ceiling, enabling once-weekly prophylactic dosing compared to 2-3 times weekly for standard therapies.
What were the key efficacy results from the XTEND-1 trial?
In the XTEND-1 trial (NCT04161495), Altuviiio demonstrated a mean annualized bleeding rate of 0.70 with a 77% reduction compared to prior factor VIII prophylaxis.
What are the most common side effects of Altuviiio?
Common adverse reactions include infusion site reactions, headache, and factor VIII inhibitor development. Hypersensitivity reactions and thromboembolic events are rare but documented.
Primary Sources
- U.S. Food and Drug Administration. FDA Approval Letter for Altuviiio (efanesoctocog alfa). February 22, 2023.
- U.S. Food and Drug Administration. Package Insert: Altuviiio (efanesoctocog alfa). February 2023.
- ClinicalTrials.gov. XTEND-1: A Study of Efanesoctocog Alfa in Patients With Hemophilia A (NCT04161495).
- Sanofi. Press Release: FDA Approves Altuviiio. February 23, 2023.
Continue Exploring
Jump into the entities behind this story.
Follow antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein developments
FDA hemophilia a alerts and antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein pipeline updates, every Monday.
This article follows our editorial standards. Report a correction via editorial contact.
